Identification

Name
CRx-139
Accession Number
DB05744
Type
Small Molecule
Groups
Investigational
Description

CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. The synergistic combination containing low doses of the glucocorticoid steroid prednisolone and the antidepressant paroxetine. This novel synergistic combination is developed for the treatment of immuno-inflammatory diseases.

Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in rheumatoid arthritis.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

CRx-139 inhibits certain pro-inflammatory biomarkers, such as TNF-alpha, IL-6 and CRP and increases the anti-inflammatory cytokine IL-10.

TargetActionsOrganism
UTumor necrosis factorNot AvailableHuman
UInterleukin-6Not AvailableHuman
UC-reactive proteinNot AvailableHuman
UInterleukin-10Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910206

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Tumor necrosis factor receptor binding
Specific Function
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct ac...
Gene Name
TNF
Uniprot ID
P01375
Uniprot Name
Tumor necrosis factor
Molecular Weight
25644.15 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Interleukin-6 receptor binding
Specific Function
Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Inv...
Gene Name
IL6
Uniprot ID
P05231
Uniprot Name
Interleukin-6
Molecular Weight
23717.965 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Low-density lipoprotein particle receptor binding
Specific Function
Displays several functions associated with host defense: it promotes agglutination, bacterial capsular swelling, phagocytosis and complement fixation through its calcium-dependent binding to phosph...
Gene Name
CRP
Uniprot ID
P02741
Uniprot Name
C-reactive protein
Molecular Weight
25038.385 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Interleukin-10 receptor binding
Specific Function
Inhibits the synthesis of a number of cytokines, including IFN-gamma, IL-2, IL-3, TNF and GM-CSF produced by activated macrophages and by helper T-cells.
Gene Name
IL10
Uniprot ID
P22301
Uniprot Name
Interleukin-10
Molecular Weight
20516.585 Da

Drug created on November 18, 2007 11:27 / Updated on November 06, 2017 06:45